Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic reviewAnthony F. Yu, Chanhyun Park, Eva Huang et al.|Expert Review of Pharmacoeconomics & Outcomes Research|2021Cited by 11